AIDS
MCID: ACQ007
MIFTS: 59

Acquired Immunodeficiency Syndrome (AIDS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Acquired Immunodeficiency Syndrome

MalaCards integrated aliases for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome 12 44 15 71
Acquired Immune Deficiency Syndrome 12 3 15
Aids 12 48
Acquired Immune Deficiency 12
Acquired Immunodeficiency 58

Classifications:

Orphanet: 58  
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:635
MeSH 44 D000163
NCIt 50 C2851
SNOMED-CT 67 62479008
ICD10 32 B20
UMLS via Orphanet 72 C0001175
Orphanet 58 ORPHA310050
UMLS 71 C0001175

Summaries for Acquired Immunodeficiency Syndrome

CDC : 3 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

MalaCards based summary : Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to human immunodeficiency virus type 1 and kaposi sarcoma. An important gene associated with Acquired Immunodeficiency Syndrome is HCP5 (HLA Complex P5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Pyrazinamide and Formaldehyde have been mentioned in the context of this disorder. Affiliated tissues include t cells, prostate and bone, and related phenotypes are cellular and digestive/alimentary

Disease Ontology : 12 A Human immunodeficiency virus infectious disease that results in reduction in the numbers of CD4-bearing helper T cells below 200 per microliter of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. Opportunistic infections are common in people with AIDS.

Related Diseases for Acquired Immunodeficiency Syndrome

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2296)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 32.7 TNF ITIH4 IL2 IL10 IFNG HLA-B
2 kaposi sarcoma 32.5 IL6 IFNA1 HLA-B CCR5
3 oral hairy leukoplakia 32.5 ITIH4 IL10 CD4
4 immune deficiency disease 32.2 TNF ITIH4 IL6 IL2 IL10 IFNG
5 immune system disease 32.2 TNF IL6 IL2 IL10 CD4 ALB
6 toxoplasmosis 32.1 TNF IL6 IL10 IFNG CCR5 CCL3
7 histoplasmosis 32.0 TNF IFNG HLA-B CD4
8 cryptococcosis 32.0 TNF IL10 IFNG CSF2 CD4
9 cytomegalovirus retinitis 32.0 TNF IL10 IFNG HLA-B CSF2 CD4
10 cryptococcal meningitis 31.9 IFNG CSF2 CD4
11 candidiasis 31.9 TNF IL6 IL2 IL10 IFNG CSF2
12 progressive multifocal leukoencephalopathy 31.8 TNF IL2 CD4
13 pneumocystosis 31.8 TNF IL6 IL2 CD4 CCR5 ALB
14 esophagitis 31.8 TNF IL6 IL10
15 encephalitis 31.8 TNF ITIH4 IL6 IL10 CCR5 CCL3
16 central nervous system lymphoma 31.7 IL6 IL2 IL10
17 lymphopenia 31.7 IL6 IL2 IL10 IFNG
18 chronic mucocutaneous candidiasis 31.7 TNF IL6 IL2 IL10 IFNG IFNA1
19 syphilis 31.6 CD4 CCR5 B2M ALB
20 diarrhea 31.6 TNF IL6 IL2 IL10 IFNG IFNA1
21 bacterial infectious disease 31.6 TNF IL6 IL10 IFNG CSF2 CD4
22 respiratory failure 31.6 TNF IL6 IL10 CD4 ALB
23 retinal detachment 31.6 TNF IL6 IL10 IFNG
24 chickenpox 31.6 TNF IL6 IL2 IL10 IFNG IFNA1
25 pancytopenia 31.5 IL6 IFNG CSF2 CD4
26 aspergillosis 31.5 TNF IL6 IL10 IFNG CSF2 CCL3
27 lymphoma, non-hodgkin, familial 31.5 IL6 IL2 CSF2 CD4 CD38 B2M
28 pericardial effusion 31.5 IL6 CD4 ALB
29 neutropenia 31.5 TNF IL6 IL2 IL10 IFNG IFNA1
30 aids dementia complex 31.5 TNF ITIH4 B2M
31 meningitis 31.4 TNF IL6 IL2 IL10 IFNG HLA-B
32 myelitis 31.4 TNF IL6 IL10
33 myocarditis 31.4 TNF IL6 IL2 IL10 IFNG IFNA1
34 uveitis 31.4 TNF IL6 IL2 IL10 IFNG HLA-B
35 exanthem 31.4 TNF IL6 IL2 IL10 IFNG IFNA1
36 pericarditis 31.4 TNF IL6 IFNG
37 purpura 31.4 TNF IL6 IL10 IFNG
38 bacterial pneumonia 31.4 TNF IL6 IL10 CD4 CCL3 ALB
39 cholangitis 31.4 TNF IL6 IL2 IL10 HLA-B CCR5
40 visceral leishmaniasis 31.4 TNF IL2 IL10 IFNG CD38 ALB
41 meningoencephalitis 31.3 TNF IL6 IL10 CD4 B2M ALB
42 lymphadenitis 31.3 TNF IL10 IFNG CD4
43 chorioretinitis 31.3 TNF IL6 IL2 IL10 IFNG CD4
44 osteomyelitis 31.3 TNF IL6 IL10 IFNG
45 penicilliosis 31.3 IFNG CD4
46 keratitis, hereditary 31.3 TNF IL6 IL10 CD4
47 nocardiosis 31.3 TNF IFNG CD4
48 bacterial sepsis 31.2 TNF IL6 IL10
49 toxic shock syndrome 31.2 TNF IL6 IL2 IL10 IFNG
50 iridocyclitis 31.2 TNF IL6 IL10 HLA-B CD4

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:



Diseases related to Acquired Immunodeficiency Syndrome

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 ALB B2M CCR5 CD38 CD4 CSF2
2 digestive/alimentary MP:0005381 9.91 ALB B2M CCR5 CD4 IFNG IL10
3 endocrine/exocrine gland MP:0005379 9.9 ALB B2M CD38 CD4 CSF2 IFNG
4 liver/biliary system MP:0005370 9.61 ALB B2M CCR5 IFNG IL10 IL2
5 neoplasm MP:0002006 9.32 ALB B2M CCR5 CSF2 IFNG IL10

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 841)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
2
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
3
Misoprostol Approved Phase 4 59122-46-2 5282381
4
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
5
Nevirapine Approved Phase 4 129618-40-2 4463
6
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
7
Zidovudine Approved Phase 4 30516-87-1 35370
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Didanosine Approved Phase 4 69655-05-6 50599
10
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
11
Ethambutol Approved Phase 4 74-55-5 3279 14052
12
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
13
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
14
Polyestradiol phosphate Approved Phase 4 28014-46-2
15
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
16
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
19
Ribavirin Approved Phase 4 36791-04-5 37542
20
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
21
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
22
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
23
Sorbitol Approved Phase 4 50-70-4 5780
24
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
25
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
26
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
27
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
28
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
29
Travoprost Approved Phase 4 157283-68-6 5282226
30
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
31
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
32
Racepinephrine Approved Phase 4 329-65-7 838
33
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
34
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
35
Desipramine Approved, Investigational Phase 4 50-47-5 2995
36
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
37
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
38
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
39
Ibuprofen Approved Phase 4 15687-27-1 3672
40
Citalopram Approved Phase 4 59729-33-8 2771
41
Norepinephrine Approved Phase 4 51-41-2 439260
42
Phenol Approved, Experimental Phase 4 108-95-2 996
43
Haloperidol Approved Phase 4 52-86-8 3559
44
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
45
deoxycholic acid Approved Phase 4 83-44-3 222528
46
Acetaminophen Approved Phase 4 103-90-2 1983
47
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
48
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
49
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
50
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676

Interventional clinical trials:

(show top 50) (show all 3876)
# Name Status NCT ID Phase Drugs
1 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
2 Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial). Unknown status NCT02337322 Phase 4 Dolutegravir;Darunavir/r
3 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
4 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
5 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
6 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
7 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
8 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
9 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
10 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
11 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
12 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
13 A Single Site, Three Arm, Open Label Comparative Preference Study to Evaluate the Preference of Consumers and Health Care Professionals for the Use of Shapes by PolyMem Wound Dressings and Shapes by PolyMem Silver Wound Dressings, Each Compared to Antibiotic Ointment Covered With a Band-aid Type Dressing (Current Standard of Practice) and to Each Other in the Post-biopsy Management of Shave Biopsies. Each Participant Serves as Own Control. A Blinded Third Party Physician Will Evaluate and Compare the Wounds Based on Photos Taken at the Various Follow-up Points.. Unknown status NCT00727870 Phase 4
14 A Study on the Fit and Behaviour of Computer-aided Design and Rapid Prototyping Fabrication of Removable Partial Dentures Unknown status NCT01191073 Phase 4
15 Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Unknown status NCT02951559 Phase 4
16 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
17 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
18 Use of Misoprostol by Families and Women as a First Aid Measure to Address Excessive Postpartum Bleeding in Home Deliveries Unknown status NCT02853552 Phase 4 Misoprostol
19 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
20 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
21 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
22 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
23 PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment Completed NCT02167386 Phase 4
24 Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults Completed NCT01025830 Phase 4 Triomune;Zerit/Epivir/Viramune
25 Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients Completed NCT00810108 Phase 4 lopinavir/ritonavir (Kaletra®) tablets
26 ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence Completed NCT03218592 Phase 4 Maraviroc Pill;Dolutegravir Pill;Truvada Pill
27 An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1. Completed NCT00144157 Phase 4 Nevirapine;Zidovudine;3TC
28 A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy Completed NCT00273988 Phase 4 nevirapine
29 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
30 A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa. Completed NCT02348177 Phase 4 lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1
31 Exploratory Controlled Prospective Randomized Trial to Compare the Efficacy and Safety of Two Different Pharmacology Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study Completed NCT01348282 Phase 4 Lithium;Rivastigmine
32 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
33 Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
34 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
35 A Randomised Comparator Study to Assess the Relative Efficacy of Genotypic Versus Virtual Phenotypic Resistance Tests in Treatment Experienced Patients With HIV Infection for Whom a Change in Therapy is Indicated Completed NCT00262717 Phase 4
36 Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation Completed NCT03314064 Phase 4 Dolutegravir 50 mg
37 Evaluating Performance, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons in Botswana During 2012-2013: The Xpert Package Rollout Evaluation Study (XPRES) Completed NCT02538952 Phase 4
38 An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function Completed NCT00717067 Phase 4 Maraviroc;Maraviroc;Ritonavir;Saquinavir;Maraviroc;Ritonavir;Saquinavir;Maraviroc;Ritonavir;Saquinavir;Maraviroc;Maraviroc;Maraviroc
39 A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa Completed NCT02028676 Phase 4 Arm A: ABC+3TC+NNRTI;Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance;Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance;Once-daily ABC+3TC;Twice-daily ABC+3TC;Continued cotrimoxazole prophylaxis
40 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo
41 Efficacy of a Computerised Physician Reminder System to Control Cardiovascular Risk Factors in HIV-infected Patients Receiving Antiretroviral Therapy: A Nested Randomised Controlled Cluster Trial Within the Swiss HIV Cohort Study Completed NCT00264394 Phase 4
42 A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks Completed NCT00082394 Phase 4 Trizivir;atazanavir;Combivir
43 A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Maraviroc in HIV Virally Suppressed Patients With Cognitive Impairment Completed NCT01449006 Phase 4 Maraviroc
44 An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects Completed NCT02634073 Phase 4 Lamivudine;Sorbitol
45 A Pilot Study of Daily TDF/FTC-based PrEP Among High-risk Toronto MSM:The PREPARATORY-5 Study Completed NCT02149888 Phase 4 Tenofovir/emtricitabine
46 Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatitis C, Genotype 1, Co-Infected With Human Immunodeficiency Virus Completed NCT02761629 Phase 4 Peg-Interferon Alpha-2A;Ribavirin
47 Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (800 mg and 400 mg, Respectively) Compared With Standard Dosing (400 mg and 200 mg/12 h) in Patients With HIV Infection Completed NCT01121809 Phase 4 Raltegravir;Etravirine
48 Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL Completed NCT00342355 Phase 4 Zidovudine;Stavudine;Didanosine;Lamivudine;Efavirenz;Lopinavir/Ritonavir
49 Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids Completed NCT00296153 Phase 4 Omega-3-acid ethyl esters 90
50 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 51 :


abacavir
abacavir sulfate
Amprenavir
Delavirdine
Delavirdine Mesylate
Didanosine
efavirenz
enfuvirtide
Immunoglobulins, Intravenous
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Ritonavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Cochrane evidence based reviews: acquired immunodeficiency syndrome

Genetic Tests for Acquired Immunodeficiency Syndrome

Anatomical Context for Acquired Immunodeficiency Syndrome

MalaCards organs/tissues related to Acquired Immunodeficiency Syndrome:

40
T Cells, Prostate, Bone, Bone Marrow, Spinal Cord, Eye, Endothelial

Publications for Acquired Immunodeficiency Syndrome

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 21066)
# Title Authors PMID Year
1
Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents. 61
33234268 2021
2
Customer relationship management analysis of outpatients in a Chinese infectious disease hospital using drug-proportion recency-frequency-monetary model. 61
33418439 2021
3
Cutaneous Head and Neck Cancers in the High-Risk Immunosuppressed Population. 61
33602516 2021
4
Coumarin-based derivatives with potential anti-HIV activity. 61
33582266 2021
5
Achieving and Maintaining Safety in Healthcare Requires Unwavering Institutional and Individual Commitments. 61
33575159 2021
6
Negative correlation between bone mineral density and subclinical fractures in patients with human immunodeficiency virus. 61
33528283 2021
7
Prevalence and evaluation of risk factors of anti-retroviral therapy failure among human immunodeficiency virus/acquired immune deficiency syndrome patients in North India. 61
33539512 2021
8
Lymphoid interstitial pneumonitis in a newly diagnosed late presenter of human immunodeficiency virus infection: a case report. 61
33526074 2021
9
Modular Approaches to Understand the Immunobiology of Human Immunodeficiency Virus Latency. 61
33600238 2021
10
Related factors for depression among Chinese men who have sex with men: A protocol for systematic review and meta-analysis. 61
33607782 2021
11
The individual, interactive, and syndemic effect of substance use, depression, education, and ethnicity on retention in HIV care. 61
33323072 2021
12
Exploring the potency of currently used drugs against HIV-1 protease of subtype D variant by using multiscale simulations. 61
32000612 2021
13
Real-world outcomes of AIDS-related Burkitt lymphoma: a retrospective study of 78 cases over a 10-year period. 61
33594656 2021
14
Primary nasal Kaposi Sarcoma in well-controlled HIV-positive patient with normal CD4 count associated with long-term nasal steroid use. 61
33533293 2021
15
Disseminated intraosseous Kaposi's sarcoma: A rare manifestation of HIV/AIDS. 61
33058479 2021
16
Pulmonary involvement in acquired immunodeficiency syndrome-associated Kaposi's sarcoma: a descriptive analysis of thin-section manifestations in 29 patients. 61
33532271 2021
17
The value of infectious disease modeling and trend assessment: a public health perspective. 61
33522327 2021
18
Implications of hematopoietic stem cells heterogeneity for gene therapies. 61
33589780 2021
19
A comparative study of multimodal magnetic resonance in the differential diagnosis of acquired immune deficiency syndrome related primary central nervous system lymphoma and infection. 61
33568094 2021
20
Recent Advances in the Synthesis and Development of Curcumin, its Combinations, Formulations and Curcumin-like Compounds as Antiinfective Agents. 61
33430722 2021
21
The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging. 61
33467074 2021
22
Intravenous drug use history is not associated with poorer outcomes after arteriovenous access creation. 61
32445833 2021
23
Hemichorea-Hemiballismus as a Presentation of Cerebritis from Intracranial Toxoplasmosis and Tuberculosis. 61
33552670 2021
24
HIV Co-Infection Among Presumptive Tuberculosis Cases and Asthmatic Patients at University of Gondar Hospital, Northwest Ethiopia. 61
33491420 2021
25
Exploring optical spectroscopic techniques and nanomaterials for virus detection. 61
32868971 2021
26
Pre-exposure prophylaxis (PrEP) awareness, attitudes and uptake willingness among young people: gender differences and associated factors in two South African districts. 61
33606603 2021
27
Investigational drugs with dual activity against HBV and HIV (Review). 61
33262821 2021
28
Specific Guanosines in the HIV-2 Leader RNA are Essential for Efficient Viral Genome Packaging. 61
33221337 2021
29
Serological Determination of Toxoplasma gondii among Sheep (Ovis aries) in Guilan Province, Iran. 61
33403841 2021
30
Genomic characterization of a new CRF01_AE/CRF07_BC case from a MSM patient in Guangdong, China. 61
33448453 2021
31
Multilevel model on longitudinal data analysis in determinants of CD4 cell count among antiretroviral therapy attendant of HIV infected adults follow up in Gondar Teaching Referral Hospital, Gonder, Ethiopia. 61
33451347 2021
32
Analysis of the Interaction Between HIV and Periodontopathic Bacteria That Reactivates HIV Replication in Latently Infected Cells. 61
32815141 2021
33
Prostate cancer presentation, treatment selection, and outcomes among men with HIV/AIDS: A clinical stage, race, and age-matched contemporary analysis. 61
32843291 2021
34
Comparison of initial high-resolution computed tomography (HRCT) features of coronavirus disease 2019 (COVID-19) pneumonia and other viral pneumonias. 61
33545786 2021
35
The Frequency of Natural Killer Cell Subsets in Patients with Acquired Immune Deficiency Syndrome with Deep Fungal Infections. 61
33603410 2021
36
Chest complications in immunocompromised patients without acquired immunodeficiency syndrome (AIDS): differentiation between infectious and non-infectious diseases using high-resolution CT findings. 61
32859382 2021
37
Patient Characteristics, Patterns, and Repair of Aneurysms in Human Immunodeficiency Virus-Positive Patients. 61
32599105 2021
38
Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection. 61
33511235 2021
39
Infectious diseases of the upper gastrointestinal tract. 61
33382485 2021
40
Near Full-Length Genomic Characterization of 16 HIV-1 CRF01_AE Primary Isolates from Guangxi, China. 61
33287627 2021
41
1,2,3-Triazole hybrids with anti-HIV-1 activity. 61
32960467 2021
42
Adherence predictor variables in AIDS patients: an empirical study using the data mining-based RFM model. 61
33509194 2021
43
Nano Co-Crystal Embedded Stimuli-Responsive Hydrogels: A Potential Approach to Treat HIV/AIDS. 61
33498151 2021
44
Management of cardiovascular diseases in HIV/AIDS patients. 61
33225472 2021
45
Health-related quality of life of patients with HIV/AIDS at a tertiary care teaching hospital in Ethiopia. 61
33468153 2021
46
Acquired immune deficiency syndrome (AIDS) and late presentation in Poland - data from Test and Keep in Care (TAK) Polska project. 61
33410278 2021
47
An AIDS Patient with Recurrent Multiple Skin Crusted Ulcerations. 61
32981329 2021
48
The association between HIV/AIDS and food insecurity at the US-Mexico border: Experiences of low-income patients in the Rio Grande Valley. 61
33241752 2021
49
Spatiotemporal Analysis of AIDS Incidence and Its Influencing Factors on the Chinese Mainland, 2005-2017. 61
33503938 2021
50
Nano-based drug delivery system: a smart alternative towards eradication of viral sanctuaries in management of NeuroAIDS. 61
33486689 2021

Variations for Acquired Immunodeficiency Syndrome

Expression for Acquired Immunodeficiency Syndrome

Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.

Pathways for Acquired Immunodeficiency Syndrome

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TNF IL6 IL2 IL10 IFNG IFNA1
2
Show member pathways
13.72 TNF IL6 IL2 IL10 IFNG IFNA1
3
Show member pathways
13.56 TNF IL6 IL2 IL10 IFNG IFNA1
4
Show member pathways
13.45 TNF IL6 IL2 IL10 CSF2 CD4
5
Show member pathways
13.35 TNF IL6 IL2 IL10 CSF2 CD4
6
Show member pathways
13.26 TNF IL6 IL2 IL10 IFNG IFNA1
7